Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VISEN PharmaceuticalsHKSE:02561 7 EV-to-FCF is -3.68 as of Aug. 29, 2026. GuruFocus rates HKSE:02561 with a GF Score™ of 7/100. The stock has 5 warning signs investors should review. Among 559 Drug Manufacturers companies, VISEN Pharmaceuticals ranks worse than 178890.7% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, VISEN Pharmaceuticals's Enterprise Value is HK$1,889.06 Mil.
VISEN Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was HK$-512.92 Mil. Therefore, VISEN Pharmaceuticals's EV-to-FCF for today is -3.68.
The historical rank and industry rank for VISEN Pharmaceuticals's EV-to-FCF or its related term are showing as below:
HKSE:02561'
s EV-to-FCF Range Over the Past 10 Years
Min: -6.85 Med: -4.21 Max: -2.97
Current: -3.68
During the past 4 years, the highest EV-to-FCF of VISEN Pharmaceuticals was -2.97. The lowest was -6.85. And the median was -4.21.
HKSE:02561's EV-to-FCF is ranked worse than 100% of 559
companies
in the Drug Manufacturers industry
Industry Median: 20.58
vs HKSE:02561: -3.68
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
VISEN Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
VISEN Pharmaceuticals's share price for today is HK$19.98.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. VISEN Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was HK$-2.491.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, VISEN Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VISEN Pharmaceuticals EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, VISEN Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where VISEN Pharmaceuticals's EV-to-FCF falls into.
VISEN Pharmaceuticals's current Enterprise Value is HK$1,889.06 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. VISEN Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was HK$-512.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VISEN Pharmaceuticals (HKSE:02561) has a EV-to-FCF of -3.68 as of Aug. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on VISEN Pharmaceuticals and its competitors. According to the industry distribution chart, VISEN Pharmaceuticals ranks #999999 out of 559 companies in the Drug Manufacturers industry.
Is VISEN Pharmaceuticals' EV-to-FCF too high?
VISEN Pharmaceuticals' current EV-to-FCF is -3.68. Based on the distribution chart, VISEN Pharmaceuticals ranks #999999 out of 559 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, VISEN Pharmaceuticals has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does VISEN Pharmaceuticals' EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, VISEN Pharmaceuticals ranks #999999 out of 559 companies for EV-to-FCF. This places VISEN Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 20.58. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.58, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on VISEN Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VISEN Pharmaceuticals's current EV-to-FCF is -3.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VISEN Pharmaceuticals stock overvalued right now?
VISEN Pharmaceuticals (HKSE:02561) has a current EV-to-FCF of -3.68. The current EV-to-FCF is -3.68. VISEN Pharmaceuticals' overall GF Score™ is 7/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For VISEN Pharmaceuticals (HKSE:02561), the current EV-to-FCF is -3.68 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.
7GF Score
Get the complete analysis for HKSE:02561
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02561 has been successfully added to your 
